{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:46Z","timestamp":1789726246129,"version":"4.0.1"},"reference-count":93,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"Importance<\/jats:title>Antibiotics are an important risk for Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS\/TEN), which are the most severe types of drug hypersensitivity reaction with a mortality rate up to 50%. To our knowledge, no global systematic review has described antibiotic-associated SJS\/TEN.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the prevalence of antibiotics associated with SJS\/TEN worldwide.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>The MEDLINE and Embase databases were searched for experimental and observational studies that described SJS\/TEN risks since database inception to February 22, 2022.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Included studies adequately described SJS\/TEN origins and specified the antibiotics associated with SJS\/TEN.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>Two reviewers (E.Y.L. and C.K.) independently selected the studies, extracted the data, and assessed the risk of bias. A meta-analysis using a random-effects model was performed in the studies that described patient-level associations. Subgroup analyses were performed to explore the heterogeneity. The risk of bias was assessed using the Joanna Briggs Institute checklist, and the certainty of evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Prevalence of antibiotic-associated SJS\/TEN was presented as pooled proportions with 95% CIs.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 64 studies included in the systematic review, there were 38 studies that described patient-level associations; the meta-analysis included these 38 studies with 2917 patients to determine the prevalence of single antibiotics associated with SJS\/TEN. The pooled proportion of antibiotics associated with SJS\/TEN was 28% (95% CI, 24%-33%), with moderate certainty of evidence. Among antibiotic-associated SJS\/TEN, the sulfonamide class was associated with 32% (95% CI, 22%-44%) of cases, followed by penicillins (22%; 95% CI, 17%-28%), cephalosporins (11%; 95% CI, 6%-17%), fluoroquinolones (4%; 95% CI, 1%-7%), and macrolides (2%; 95% CI, 1%-5%). There was a statistically significant heterogeneity in the meta-analysis, which could be partially explained in the subgroup analysis by continents. The overall risk of bias was low using the Joanna Briggs Institute checklist for case series.<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>In this systematic review and meta-analysis of all case series, antibiotics were associated with more than one-quarter of SJS\/TEN cases described worldwide, and sulfonamide antibiotics remained the most important association. These findings highlight the importance of antibiotic stewardship, clinician education and awareness, and weighing the risk-benefit assessment of antibiotic choice and duration.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.6378","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T16:04:39Z","timestamp":1676477079000},"page":"384","source":"Crossref","is-referenced-by-count":79,"title":["Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"],"prefix":"10.1001","volume":"159","author":[{"given":"Erika Yue","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, Eliot Phillipson Clinician-Scientist Training Program, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Knox","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Jane","family":"Phillips","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Centre for Clinical Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Perth, Western Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi220074r1","first-page":"3","article-title":"Drug causality in Stevens-Johnson syndrome\/toxic epidermal necrolysis in Europe: analysis of 10 years RegiSCAR-Study.","volume":"25","author":"Mockenhaupt","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"doi220074r2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults.","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi220074r3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK.","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi220074r4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"6","key":"doi220074r6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","article-title":"Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis.","volume":"157","author":"Hoffman","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi220074r7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs: the EuroSCAR-study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi220074r8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4065\/mcp.2009.0379","article-title":"Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.","volume":"85","author":"Wetter","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"doi220074r9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis.","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"doi220074r10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamadermatol.2017.0160","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health working group.","volume":"153","author":"Maverakis","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi220074r11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"21","key":"doi220074r12","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1001\/jama.2014.839","article-title":"Recurrence and mortality following severe cutaneous adverse reactions.","volume":"311","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"doi220074r13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"doi220074r14","doi-asserted-by":"publisher","first-page":"k3155","DOI":"10.1136\/bmj.k3155","article-title":"Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study.","volume":"362","author":"Olesen","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"doi220074r15","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi220074r16","doi-asserted-by":"publisher","first-page":"187.e1","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220074r17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4097\/kjae.2017.70.2.144","article-title":"Central limit theorem: the cornerstone of modern statistics.","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J Anesthesiol"},{"issue":"7650","key":"doi220074r19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"doi220074r20","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.burns.2021.08.009","article-title":"Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome.","volume":"48","author":"de Bustros","year":"2022","journal-title":"Burns"},{"issue":"4","key":"doi220074r21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/pde.v38.4","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome\/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: a 25-year retrospective study at a single tertiary care center.","volume":"38","author":"Gleghorn","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"doi220074r22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1203475420982550","article-title":"Retrospective study of patients with SJS\/TEN treated at a tertiary burn unit in Canada: overview of 17 years of treatment.","volume":"25","author":"Olteanu","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"doi220074r23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/ijd.v60.5","article-title":"A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).","volume":"60","author":"Singh","year":"2021","journal-title":"Int J Dermatol"},{"key":"doi220074r24","first-page":"45","article-title":"Factors predicting the outcome in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study over a 5-year period.","volume":"183","author":"Thakur","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi220074r25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.6","article-title":"Severe cutaneous adverse drug reactions: incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt.","volume":"33","author":"Abou-Taleb","year":"2020","journal-title":"Dermatol Ther"},{"issue":"B","key":"doi220074r26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3889\/oamjms.2020.4906","article-title":"The link between HLA-B alleles and causative drugs in Vietnamese patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis.","volume":"8","author":"Huyen","year":"2020","journal-title":"Open Access Maced J Med Sci"},{"issue":"4","key":"doi220074r27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.burns.2019.10.008","article-title":"Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.","volume":"46","author":"Yang","year":"2020","journal-title":"Burns"},{"issue":"11","key":"doi220074r28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/ijd.v58.11","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study.","volume":"58","author":"Carrasquillo","year":"2019","journal-title":"Int J Dermatol"},{"issue":"10","key":"doi220074r29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/ijd.v58.10","article-title":"A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016.","volume":"58","author":"Chan","year":"2019","journal-title":"Int J Dermatol"},{"key":"doi220074r30","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4917024","article-title":"Ocular and mucocutaneous sequelae among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in Togo.","volume":"2019","author":"Saka","year":"2019","journal-title":"Dermatol Res Pract"},{"issue":"9","key":"doi220074r31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/ijd.v58.9","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience.","volume":"58","author":"Zhang","year":"2019","journal-title":"Int J Dermatol"},{"issue":"2","key":"doi220074r32","first-page":"184","article-title":"Causative factors and clinical outcome in Steven Johnson syndrome and toxic epidermal necrolysis.","volume":"31","author":"Noor","year":"2017","journal-title":"J Postgrad Med Inst"},{"issue":"3","key":"doi220074r33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12519-016-0057-3","article-title":"Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital.","volume":"13","author":"Techasatian","year":"2017","journal-title":"World J Pediatr"},{"issue":"5","key":"doi220074r34","doi-asserted-by":"publisher","first-page":"490.e1","DOI":"10.1016\/j.jpurol.2017.01.018","article-title":"Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"13","author":"Van Batavia","year":"2017","journal-title":"J Pediatr Urol"},{"issue":"9","key":"doi220074r35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4103\/0366-6999.204929","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 88 Chinese patients.","volume":"130","author":"Wang","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"doi220074r36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.burns.2016.07.026","article-title":"Steven Johnson syndrome and toxic epidermal necrolysis in a burn unit: a 15-year experience.","volume":"43","author":"McCullough","year":"2017","journal-title":"Burns"},{"issue":"11","key":"doi220074r37","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention.","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"issue":"3","key":"doi220074r38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaip.2017.02.013","article-title":"Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study.","volume":"5","author":"Dibek Misirlioglu","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"doi220074r39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5415\/apallergy.2016.6.1.43","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013.","volume":"6","author":"Suwarsa","year":"2016","journal-title":"Asia Pac Allergy"},{"issue":"8","key":"doi220074r40","first-page":"A5122","article-title":"Risk factors and mortality among patients with severe muco-cutaneous drug reactions.","volume":"62","author":"Cr\u00fcger","year":"2015","journal-title":"Dan Med J"},{"issue":"1","key":"doi220074r41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/BCR.0000000000000208","article-title":"A 15-year review of pediatric toxic epidermal necrolysis.","volume":"36","author":"Quirke","year":"2015","journal-title":"J Burn Care Res"},{"key":"doi220074r42","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.2147\/DDDT","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People\u2019s Republic of China.","volume":"8","author":"Sun","year":"2014","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"doi220074r43","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ijd.2015.54.issue-8","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience.","volume":"54","author":"Lalosevic","year":"2015","journal-title":"Int J Dermatol"},{"issue":"5","key":"doi220074r44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/ijd.2013.52.issue-5","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.","volume":"52","author":"Saka","year":"2013","journal-title":"Int J Dermatol"},{"issue":"6","key":"doi220074r45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.4103\/0378-6323.102367","article-title":"An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.","volume":"78","author":"Choon","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"doi220074r46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit.","volume":"67","author":"Firoz","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi220074r47","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/jdv.2013.27.issue-5","article-title":"SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population.","volume":"27","author":"Hu","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi220074r48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients.","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"4","key":"doi220074r49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"doi220074r50","first-page":"15","article-title":"Epidemiological study of Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective analysis of Southern Taiwanese population during 2002 to 2007.","volume":"27","author":"Huang","year":"2009","journal-title":"Zhonghua Pifuke Yixue Zazhi"},{"issue":"4","key":"doi220074r51","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jaad.2008.11.884","article-title":"Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.","volume":"60","author":"Wanat","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi220074r52","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/ijd.2009.48.issue-10","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"issue":"8","key":"doi220074r53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/pds.1105","article-title":"Cutaneous adverse drug reactions: a 9-year study from a south Indian hospital.","volume":"14","author":"Sushma","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"doi220074r54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century.","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"issue":"11","key":"doi220074r55","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum.","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"issue":"6","key":"doi220074r56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ijd.1993.32.issue-6","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand.","volume":"32","author":"Leenutaphong","year":"1993","journal-title":"Int J Dermatol"},{"issue":"9","key":"doi220074r57","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell\u2019s syndrome).","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"issue":"10","key":"doi220074r58","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamadermatol.2021.3154","article-title":"Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a pan-European multicenter study.","volume":"157","author":"Kridin","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi220074r59","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ijd.v59.2","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis\u2014retrospective review of cases in a high complexity hospital in Brazil.","volume":"59","author":"Medeiros","year":"2020","journal-title":"Int J Dermatol"},{"issue":"1","key":"doi220074r60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cea.v50.1","article-title":"Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: a 9-year experience in a tertiary care paediatric hospital setting.","volume":"50","author":"Liccioli","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"doi220074r61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5021\/ad.2019.31.5.545","article-title":"Severe cutaneous adverse reactions: a single-center retrospective study of 173 patients in China.","volume":"31","author":"Xu","year":"2019","journal-title":"Ann Dermatol"},{"issue":"7","key":"doi220074r62","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/09546634.2019.1568380","article-title":"Stevens Johnson syndrome and toxic epidermal necrolysis\u2014an Australian analysis of treatment outcomes and mortality.","volume":"30","author":"Tran","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi220074r63","first-page":"59","article-title":"Steven-Johnson syndrome and toxic epidermal necrolysis at a tertiary care centre in South India: a 12 year retrospective analysis.","volume":"29","author":"Kuntoji","year":"2019","journal-title":"J Pakistan Assoc Dermatol"},{"issue":"4","key":"doi220074r64","first-page":"421","article-title":"An epidemiological study of Stevens-Johnson syndrome and toxic epidermal necrolysis during 2010-2015 at Shahid Faghihi hospital, Shiraz, Iran.","volume":"43","author":"Talebi","year":"2018","journal-title":"Iran J Med Sci"},{"issue":"11","key":"doi220074r65","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States.","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi220074r66","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/15569527.2017.1301947","article-title":"Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study.","volume":"36","author":"Wang","year":"2017","journal-title":"Cutan Ocul Toxicol"},{"issue":"2","key":"doi220074r67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40801-017-0105-x","article-title":"Characterization of Stevens-Johnson syndrome and toxic epidermal necrolysis among patients admitted to Kenyatta National Hospital: a retrospective cross-sectional study.","volume":"4","author":"Irungu","year":"2017","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"doi220074r68","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4103\/njcp.njcp_122_16","article-title":"Drug-induced Stevens-Johnson syndrome in Indian population: a multicentric retrospective analysis.","volume":"20","author":"Hirapara","year":"2017","journal-title":"Niger J Clin Pract"},{"issue":"1","key":"doi220074r69","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2014treatment and outcome.","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"issue":"2","key":"doi220074r70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5372\/1905-7415.0902.386","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a retrospective study at Srinagarind Hospital, Khon Kaen, Thailand 1992-2012.","volume":"9","author":"Paipool","year":"2015","journal-title":"Asian Biomed"},{"issue":"2","key":"doi220074r71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaip.2014.10.002","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system.","volume":"3","author":"Blumenthal","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"doi220074r72","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/237821","article-title":"Retrospective analysis of corticosteroid treatment in Stevens-Johnson syndrome and\/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navamindradhiraj University, Bangkok.","volume":"2014","author":"Roongpisuthipong","year":"2014","journal-title":"Dermatol Res Pract"},{"issue":"7","key":"doi220074r73","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jde.2014.41.issue-7","article-title":"Clinical profiles of Stevens-Johnson syndrome among Thai patients.","volume":"41","author":"Limpawattana","year":"2014","journal-title":"J Dermatol"},{"issue":"4","key":"doi220074r74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093543","article-title":"Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis.","volume":"9","author":"Knight","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"doi220074r75","first-page":"87","article-title":"Severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap in children, a 10 years survey.","volume":"22","author":"Layegh","year":"2012","journal-title":"Eur J Pediatr Dermatol"},{"issue":"9","key":"doi220074r76","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/qjmed\/hcs078","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.","volume":"105","author":"Kannenberg","year":"2012","journal-title":"QJM"},{"issue":"2","key":"doi220074r77","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/0022-3859.81865","article-title":"Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.","volume":"57","author":"Barvaliya","year":"2011","journal-title":"J Postgrad Med"},{"issue":"7","key":"doi220074r78","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/ijd.2010.49.issue-7","article-title":"Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.","volume":"49","author":"Ding","year":"2010","journal-title":"Int J Dermatol"},{"issue":"3","key":"doi220074r79","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4103\/0378-6323.41369","article-title":"Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome.","volume":"74","author":"Sharma","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"doi220074r80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/ICO.0b013e31802eb264","article-title":"Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.","volume":"26","author":"Chang","year":"2007","journal-title":"Cornea"},{"issue":"5","key":"doi220074r81","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4103\/0378-6323.16782","article-title":"Carbamazepine\u2014the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years.","volume":"71","author":"Devi","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"doi220074r82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis.","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"issue":"3","key":"doi220074r83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00006454-198205000-00005","article-title":"Stevens-Johnson syndrome in children.","volume":"1","author":"Ginsburg","year":"1982","journal-title":"Pediatr Infect Dis"},{"issue":"1 pt 1","key":"doi220074r84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-156-1-201201030-00006","article-title":"Distinguishing case series from cohort studies.","volume":"156","author":"Dekkers","year":"2012","journal-title":"Ann Intern Med"},{"issue":"12","key":"doi220074r85","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/S2542-5196(21)00280-1","article-title":"Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study.","volume":"5","author":"Browne","year":"2021","journal-title":"Lancet Planet Health"},{"issue":"8","key":"doi220074r86","first-page":"87","article-title":"A systematic review of Stevens-Johnson syndrome and\/or toxic epidermal necrolysis over a period of 20 years in Thailand.","volume":"101","author":"Roongpisuthipong","year":"2018","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"doi220074r87","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1590\/abd1806-4841.20175171","article-title":"Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis.","volume":"92","author":"Deng","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"8","key":"doi220074r88","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions.","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"doi220074r89","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2019.12.025","article-title":"Association of HLA-A*11:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients.","volume":"140","author":"Nakamura","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi220074r90","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians.","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"9265","key":"doi220074r91","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0140-6736(00)04519-0","article-title":"Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.","volume":"357","author":"Enne","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"doi220074r92","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"doi220074r93","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00002018-199614040-00001","article-title":"Cotrimoxazole: rationale for re-examining its indications for use.","volume":"14","author":"Howe","year":"1996","journal-title":"Drug Saf"},{"key":"doi220074r5","volume-title":"Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends","author":"Shear","year":"2018"},{"key":"doi220074r18","volume-title":"Joanna Briggs Institute Reviewer\u2019s Manual","author":"Moola","year":"2017"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2801093\/jamadermatology_lee_2023_oi_220074_1681833191.17239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T23:19:29Z","timestamp":1701904769000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2801093"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.6378","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}